Post-Traumatic Headache clinical trials at UCSD
1 in progress, 1 open to new patients
A Study Comparing 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of PPTH
open to eligible people ages 18-70
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of fremanezumab in adult patients aged 18 to 70 years, inclusive, for the prevention of PPTH. Patients will provide written informed consent and during study visits they will use an electronic diary application daily, to report their headache status and other health information. Efficacy and immunogenicity status will be captured periodically and at study termination. The safety will be evaluated through adverse event report, concomitant medication inquiries, ECGs, clinical laboratory tests and physical examination. Additional evaluations will include pharmacokinetic, biomarker, and pharmacogenomics.
San Diego, California and other locations